Abstracts Archive - Page 954 of 2425 - ACR Meeting Abstracts

Abstract Number: PP09 • 2019 ACR/ARP Annual Meeting
Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius
Dalilah Kalla¹, ¹Lupus Alert, Rose Hill, Plaines Wilhems, Mauritius

Background/Purpose: Growing up in the small island of Mauritius, I received the unexpected diagnosis of lupus at the young age of 13. The journey that…
Abstract Number: PP10 • 2019 ACR/ARP Annual Meeting
The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis
Shannan O'Hara-Levi¹, ¹Staten Island, New York

Background/Purpose: Up until a few years ago, my 30+ year journey with Polyarticular Juvenile Rheumatoid was treated mostly with medication management alone. I was diagnosed…
Abstract Number: 2045 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets
Taylor Koenig¹, Nicholas Young ², Giancarlo Valiente ³, Ifeoma Okafor ⁴, Emily Schwarz ⁵, Peter Harb ⁵, Caitlin Henry ¹, Kyle Jablonski ⁶, Lai-Chu Wu ⁴, Eli Roberson ⁷ and Wael Jarjour ⁸, ¹Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ³The Ohio State University, Columbus, ⁴Ohio State College of Medicine, Columbus, ⁵The Ohio State University Wexner Medical Center, Columbus, OH, ⁶The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ⁷Washington University at St.Louis, St.Louis, MO, ⁸Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus is an autoimmune disease characterized by chronic inflammation. We have previously shown that TLR7 and TLR8 are significantly upregulated in PBMCs…
Abstract Number: 2703 • 2019 ACR/ARP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices
Sarah Ringold ¹, George Tomlinson ², Pamela Weiss ³, Laura Schanberg ⁴, Mary Ellen Riordan ⁵, Anne Dennos ⁶, Vincent Del Gaizo ⁷, Katherine Murphy ⁸, Brian Feldman ⁹ and Yukiko Kimura¹⁰, ¹Seattle Children's, Seattle, ²University of Toronto, Toronto, ON, Canada, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Duke University Medical Center, Durham, NC, ⁵Joseph M Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, NJ, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Childhood Arthritis & Rheumatology Research Alliance, Whitehouse Station, NJ, ⁸Louisiana Office of Public Health, New Orleans, LA, ⁹University of Toronto & The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH
Background/Purpose: There continues to be uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance…
Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Jeffrey Sparks¹, Susan Malspeis ¹, Jill Hahn ², Andrea Roberts ², Laura Kubzansky ² and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…
Abstract Number: 2823 • 2019 ACR/ARP Annual Meeting
Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Jill Norris¹, Elizabeth Bemis ², Marie Feser ³, M. Kristen Demoruelle ⁴, Jennifer Seifert ⁵, Michael Weisman ⁶, Jane Buckner ⁷, Peter Gregersen ⁸, Ted Mikuls ⁹, James O'Dell ⁹, Richard M. Keating ¹⁰, Kevin Deane ³ and V. Michael Holers ⁵, ¹Colorado School of Public Health, Aurora, ²University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Benaroya Research Institute, Seattle, WA, ⁸Feinstein Institutes for Medical Research, Manhasset, NY, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰Scrippshealth, La Jolla
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibodies are typically elevated prior to the onset of seropositive RA. Screening for autoantibody (aAb) positive individuals is a means to…
Abstract Number: 1 • 2019 ACR/ARP Annual Meeting
Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Mahamudul Haque ¹, Bhanupriya Madarampalli ² and Salahuddin Ahmed ³, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, Spokane, WA, ²University of Washington, Seattle, WA, ³Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and joint destruction caused by pro-inflammatory cytokines. Progressive joint damage is also an…
Abstract Number: 2 • 2019 ACR/ARP Annual Meeting
Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus
Loqmane Seridi¹, Matteo Cesaroni ¹, Matthew Loza ¹, Jessica Schreiter ¹, Kristen Sweet ¹, Yevgeniya Orlovsky ¹, Isabelle Baribaud ¹, Ashley Orillion ¹, Peter Lipsky ², Ronald van Vollenhoven ³, Bevra Hahn ⁴, George Tsokos ⁵, Marc Chevrier ¹, Shawn Rose ¹, Frédéric Baribaud ¹ and Jarrat Jordan ¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴University of California, Los Angeles, CA, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic Lupus Erythematous (SLE) is a clinically and biologically diverse disease, for which only one new therapy has been approved in the past 60…
Abstract Number: 3 • 2019 ACR/ARP Annual Meeting
Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss
Ane Larrañaga-Vera¹, Francisco Conesa-Buendia ², Bruce Cronstein ³ and Aranzazu Mediero ², ¹NYU Langone Health, New York, NY, ²IIS-FUNDACION JIMENEZ DIAZ, Madrid, Spain, ³NYU Langone, New York
Background/Purpose: Tenofovir is an anti-retroviral agent commonly used to treat human immunodeficiency virus (HIV)-infected patients as part of the drug regimen known as highly active…
Abstract Number: 4 • 2019 ACR/ARP Annual Meeting
AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers¹, Aditi Kuppe ¹, Cindy Strehl ¹, Marieluise Kirchner ², Frank Buttgereit ³ and Timo Gaber ¹, ¹Charite University Hospital Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine, BIH Core Facility Proteomics, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Adenosine and its nucleotides represent crucial immunomodulators in the extracellular environment. ATP and ADP are released from stressed cells in states of inflammation, whereas…
Abstract Number: 5 • 2019 ACR/ARP Annual Meeting
Interferon Kappa Promotes the Development of Psoriasis
Mehrnaz Gharaee-Kermani¹, Shannon Estadt ¹, Sonya Wolf-Fortune ¹, Johann Gudjonsson ¹ and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI
Background/Purpose: Psoriasis is a one of the most common chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of…
Abstract Number: 6 • 2019 ACR/ARP Annual Meeting
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹ and Salahuddin Ahmed ², ¹Washington State University Spokane, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and…
Abstract Number: 7 • 2019 ACR/ARP Annual Meeting
Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis
Chenyang Lu ¹, Ray Ohara ², Phillip Campbell ¹, Yuxuan Du ³, Alexander Stinson ², Jonatan Hervoso ³, Ellen Cealey ³, David Fox ⁴ and M Amin⁵, ¹the University of Michigan, Ann Arbor, MI, ²Washington University, St. Louis, MO, ³the University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disorder featured by synovial hyperplasia, inflammatory cell infiltration and presence of anti-citrullinated peptide antibodies (ACPAs) in sera.…
Abstract Number: 8 • 2019 ACR/ARP Annual Meeting
CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling
Jieun Shin¹, Nina Ha ¹, Daekwon Bae ¹, Dong-hyeon Suh ¹, Ji-yeon Baek ¹, Jae Hyun Jun ¹, Yong Jae Lee ¹, Young Il Choi ¹, Keun Ho Ryu ¹, Gi Soo Youn ² and Jinseu Park ³, ¹CKD Research Institute, Yongin-si, Republic of Korea, ²Department of Biomedical Science, Hallym University, Chuncheon, Republic of Korea, ³Department of Biomedical Science, Hallym University, Chuncheon
Background/Purpose: Inhibition of HDAC6 has been proposed beneficial and therapeutic effects in inflammatory diseases. CKD-506, a potent and selective oral HDAC6 inhibitor, has anti-inflammatory and…
Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Julian Torres Vazquez¹, Alejandro Corzo Cruz ², David Alberto Comoto Santacruz ² and Omar Eloy Muñoz Monroy ¹, ¹Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, ²Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].